Edition:
India

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

38.21USD
21 Sep 2020
Change (% chg)

$-1.05 (-2.67%)
Prev Close
$39.26
Open
$38.50
Day's High
$38.54
Day's Low
$37.70
Volume
883,471
Avg. Vol
476,543
52-wk High
$48.25
52-wk Low
$31.43

Select another date:

Fri, Sep 18 2020

Photo

EU pays $384 million for Sanofi-GSK COVID vaccine as WHO scheme deadline looms

BRUSSELS/PARIS The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi and GSK in its second such deal to secure supplies, as a deadline for joining the World Health Organization's (WHO) vaccine purchase programme looms.

Sanofi, GSK launch trial for COVID-19 protein-based vaccine

PARIS French drugmaker Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based COVID-19 vaccine candidate, and aimed to reach the final testing stage by December. | Video

Sanofi, GSK launch trial for COVID-19 protein-based vaccine

PARIS French drugmaker Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based COVID-19 vaccine candidate, and aimed to reach the final testing stage by December. | Video

UPDATE 2-Sanofi, GSK launch trial for COVID-19 protein-based vaccine

* Final testing stage expected to start in December (Recasts with detail, context)

GSK, partner Vir join race to find COVID-19 antibody treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.

GSK, partner Vir join race to find COVID-19 antibody treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.

GSK, partner Vir join race to find COVID-19 antibody treatment

Aug 31 GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.

U.S. FDA approves GlaxoSmithKline's blood cancer drug

The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer.

U.S. FDA approves GlaxoSmithKline's blood cancer drug

The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer.

U.S. FDA approves GlaxoSmithKline's blood cancer drug

Aug 5 The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer.

Select another date: